Grants Search Results

Dr. Ruff and colleagues will develop a targeted medical therapy for adamantinomatous craniopharyngioma, a brain tumor that affects children and causes lifelong vision loss, hormone problems, and cognitive impairment in the majority of survivors. Currently, the only treatments are surgery and radiation, which often cause irreversible damage to the developing brain, and despite this the tumor frequently comes back requiring repeated interventions. Combining two existing FDA-approved medications to shrink these tumors dramatically, Dr. Ruff and colleagues will study how likely these medications are to work in patients with this tumor. By analyzing tumor samples for the medication target and patient responses, Dr. Ruff and team will design a clinical trial that could transform care for children with this disease.

Many children with bone tumors cannot be cured. This is true in particular if the tumor has come back. Dr. Gottschalk and colleagues will use the immune system to fight cancer. In their approach, they will take immune cells from patients and train them in the laboratory to fight cancer. Dr. Gottschalk and team's training methods willl consist of inserting a gene into immune cells that are a called T-cells. Once the cells have completed training in the laboratory, they are given back to patients. A second gene is inserted into T cells so that the T cells can grow better in patients after infusion. Dr. Gottschalk and colleagues will figure out the best structure of the second gene and will perform laboratory studies to determine which T cell works best, resulting in selecting the best T cell product for a future clinical study for children with bone tumors.

Acute myeloid leukemia (AML) is a high-risk blood cancer in children. Even after intensive chemotherapy and bone marrow transplant, small numbers of leukemic cells, called measurable residual disease (MRD), can persist and later cause relapse. Current hospital tests examine large mixtures of cells and can miss these dangerous clones, causing clinicians to underestimate a child's relapse risk. Dr. Furlan and team will apply advanced single-cell genomic technologies to profile tens of thousands of cells from each child, pinpoint rare residual leukemia cells, and define the programs that allow them to survive treatment. Using these insights, Dr. Furlan and colleagues will develop practical, more sensitive MRD assays that children's hospitals could implement to better identify which patients are truly in deep remission and which remain at high risk, guiding earlier intervention and improving long-term cure rates for children with AML.

This grant is generously supported by Super Soph's Pediatric Cancer Research Fund, a St. Baldrick's Hero Fund. Sophie Rossi was diagnosed with AML at 3 months of age. Throughout her courageous battle, she was always smiling, always joyful. This fund was created to honor her spunky, sweet spirit by funding research to find cures for AML and all childhood cancers.

Dr. Boelens and colleagues will study how the immune system recovers after a bone marrow transplant in children with leukemia. These transplants can cure cancer, but some children relapse or develop a serious complication called chronic graft-versus-host disease, where the donor immune system attacks the child's tissues. Dr. Boelens and team will focus on the thymus, an organ that trains new immune cells but is easily damaged by chemotherapy and radiation. Dr. Boelens and colleagues will measure how well the thymus works and how immune cells grow during the first year after transplant. Dr. Boelens will confirm their findings by working with many hospitals through a large pediatric transplant network. By finding early warning signs of poor recovery, Dr. Boelens and colleagues will help doctors identify children at high risk and guide more personalized care so that more children survive transplant and grow up healthy, with fewer long-term complications.

Ewing sarcoma (EwS) is a bone and soft tissue tumor that most commonly affects children and young adults (AYA). Patients with relapsed/refractory (R/R) EwS continue to face dismal outcomes. While chemotherapy backbones are effective in patients with R/R EwS, outcomes are insufficient, and there is a need to identify combination strategies with novel agents to improve outcomes. Dr. Ganapathi and colleagues have found that EwS is critically dependent on the menin protein, which cooperates with the fusion protein EWS::FLI1 to drive growth and metastasis. Lab and model studies show that blocking menin with Revumenib (FDA approved for pediatric leukemias) powerfully suppresses tumor invasion and metastasis. Dr. Ganapathi and lab will conduct an early phase clinical trial of Revumenib combined with chemotherapy. This combination will ultimately improve outcomes for patients with R/R EwS.

This grant is generously supported by JC Strong, a St. Baldrick’s Hero Fund, established in honor of Jackson Kalbhenn to celebrate his survivorship. Jackson was 5 years old when he was diagnosed with Ewing sarcoma. After 14 cycles of aggressive chemotherapy, 69 nights in the hospital, and a resection on his left leg, his treatment was complete. Today, Jackson shows no evidence of disease and enjoys an active life filled with all things sports related. Through JC Strong, his family hopes to make meaningful difference for every child and family facing Ewing sarcoma.

This grant funds a student to complete work in pediatric oncology research for the summer. Treating brain tumors in children is challenging because many medicines cannot reach the tumor. A natural barrier formed by the brain's blood vessels protects the brain but also blocks helpful drugs, and there is still a lack of clear understanding of how this barrier behaves in different pediatric brain tumors. Dr. Straehla and colleagues will study blood vessels across a wide range of childhood brain and spinal cord tumors by selecting samples and building tissue microarrays, which will allow many small pieces of tissue to be analyzed together. The samples will be used to identify proteins found in tumor blood vessels, including potential treatment targets. By comparing findings across tumor types and linking them with patient details, Dr. Straehla and team will create one of the first maps of vascular changes in pediatric brain tumors, informing future therapies. This work is being completed under the mentorship of Dr. Joelle Straehla.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Orlando Health Arnold Palmer Hospital for Children's goal is to work towards providing personalized medicine to improve cancer outcomes for children. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Louisiana State University Health Sciences Center and Manning Family Children's is committed to improving outcomes during and after cancer treatment. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Children's Hospital of The King's Daughters (CHKD) cares for children diagnosed with cancer in southeast Virginia and northeast North Carolina. Clinical trials at CHKD allow for children throughout their great region to access novel agents without traveling far from home. This grant supports the Clinical Research Team to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Golisano Children's Hospital is committed to providing excellent care to all children, adolescents and young adults who are being treated or have been treated with cancer in their region. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Oklahoma Children's has joined the Beat Childhood Cancer Research Consortium, a group of 50+ hospitals that work together to develop new treatments towards treating pediatric cancer. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The UIC/Rush/Stroger Medical Center Children's Oncology Group Program offers pediatric patients the opportunity to enroll onto COG clinical trials, offering cutting edge treatment, optimal care, and comprehensive follow-up. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant is named for the Do It for Dominic Fund which honors the memory of Dominic Cairo who battled non-Hodgkins lymphoma and was a hero to his school and community. His family and friends continue to raise funds and support research in the hopes that no child has to go through what Dominic endured.

The Center for Cancer and Blood Disorders at Phoenix Children's offers early-phase clinical trials for children with cancer, enabling patients to receive the newest, most promising treatments available. This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Medulloblastoma is the most common malignant brain tumor in children. While multimodal therapy for medulloblastoma at diagnosis has resulted in improved outcomes, there are very few options at the time of relapse, with overall poor survival. Preclinical data have shown anti-tumor activity with liothyronine (T3, activated thyroid hormone) in medulloblastoma models. T3 has safety data and dosing which are available for children. Dr. Ronsley and colleagues will translate these preclinical findings into a clinical trial, which will treat children and adolescents with relapsed medulloblastoma with T3 in combination with chemotherapy and evaluate both safety and efficacy and the role for monitoring with liquid biopsy.

This grant is named for Hannah’s Heroes, a Hero Fund established to honor Hannah Meeson. At age 6 she was diagnosed with anaplastic medulloblastoma. After a relapse and additional treatment, Hannah currently shows no evidence of disease. Throughout her treatments, Hannah never complained and remained positive and happy. This fund pays tribute to her fight by raising awareness and funding for all childhood cancers because kids like Hannah “are worth fighting for.”